Welcome to our dedicated page for Revance Therapeutics news (Ticker: RVNC), a resource for investors and traders seeking the latest updates and insights on Revance Therapeutics stock.
Revance Therapeutics, Inc. (symbol: RVNC) is a specialty biopharmaceutical company dedicated to the development, manufacturing, and commercialization of innovative botulinum toxin products for various aesthetic and therapeutic uses. Leveraging its proprietary portfolio of botulinum toxin compounds and the patented TransMTS® peptide delivery system, Revance aims to address unmet needs in the $3 billion neurotoxin market.
The company’s unique TransMTS technology allows for the delivery of botulinum toxin A in two distinctive formulations: a needle-free topical form and an injectable form that targets the site of injection for a potentially longer-lasting effect. Revance is actively pursuing clinical development for two main product candidates: Topical RT001 and Injectable RT002. RT001 is a topical gel with the potential to become the first commercially available non-injectable botulinum toxin dose form.
Additionally, Revance has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Their primary products, DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics, are central to their aesthetic and therapeutic offerings.
Revance operates through two main business segments: Product and Service. The Products segment, which generates the majority of the company’s revenue, focuses on the research and development of aesthetic and therapeutic products. Recent achievements and ongoing developments reflect the company’s commitment to advancing the field of neuromodulation.
Revance Therapeutics, Inc. (NASDAQ: RVNC) will participate in the 22nd Annual Needham Virtual Healthcare Conference from April 17-20, 2023. CFO Tobin Schilke is set to engage in a fireside chat on April 18 at 12:45 PM ET. The conference's live audio webcast can be accessed via the company's Investor Relations page, with a replay available for 90 days post-event. Revance focuses on innovative aesthetic and therapeutic solutions, including the DAXXIFY® injection for muscle movement disorders. Headquartered in Nashville, Tennessee, Revance also operates in Newark, Pleasanton, and Irvine, California.
Revance Therapeutics, Inc. (RVNC) announced its participation in upcoming investor conferences. CEO Mark J. Foley will engage in a fireside chat at the Barclays Global Healthcare Conference on
Revance specializes in innovative aesthetic and therapeutic solutions, including DAXXIFY® and the RHA® Collection, enhancing patient and physician experiences.
The facial injectable market was valued at
FAQ
What is the current stock price of Revance Therapeutics (RVNC)?
What is the market cap of Revance Therapeutics (RVNC)?
What does Revance Therapeutics, Inc. specialize in?
What is the TransMTS® peptide delivery system?
What are the main products of Revance Therapeutics?
What is RT001?
What are the business segments of Revance Therapeutics?
How does Revance's TransMTS technology benefit its products?
What is the significance of DaxibotulinumtoxinA?
What is the RHA Collection?
What is the HintMD platform?
How does Revance's Product segment contribute to its revenue?
